Dateline: Mon, 13 Mar 2006
freeNewsArticles Story Summary: “MALVERN, PA – Mar. 13 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’) today announced that it has been awarded an R01 grant from the National Institutes of Health to accelerate development of its new DiscoveryDot(TM) High Throughput Screening technology for drug discovery. The NIH grant is part of the Screening Roadmap, designed to produce innovative chemical tools for use in biological research and drug development. Out of 8 recipients of grants pursuant to the original RFA, Reaction Biology is the only private corporation to be so awarded. ”
A R T I C L E:
MALVERN, PA (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (“RBC”) today announced that it has been awarded an R01 grant from the National Institutes of Health to accelerate development of its new DiscoveryDot(TM) High Throughput Screening technology for drug discovery. The NIH grant is part of the Screening Roadmap, designed to produce innovative chemical tools for use in biological research and drug development. Out of 8 recipients of grants pursuant to the original RFA, Reaction Biology is the only private corporation to be so awarded.
The grant provides for $1,828,000 in funding over four years. It originates from the National Human Genome Research Institute and funds two specific areas: 1) The further development of RBC’s proprietary spray deposition technology for High Throughput Screening (“HTS”) reaction activation, and 2) The development of enhanced microarray printing technology for use in RBC’s DiscoveryDot(TM) HTS system and elsewhere. The DiscoveryDot(TM) technology currently is capable of screening up to 6,600 individual reactions at 1 nanoliter volume on a 1-by-3 inch glass slide. Millions of dollars can be saved on large scale screening campaigns through reagent savings, process costs, and labor reduction. RBC intends to further increase the throughput of its HTS process through the development of enhanced microarray printing and automated spray deposition.
About Reaction Biology Corporation
Reaction Biology, based in Malvern, Pa., provides high throughput screening services to the biotechnology and pharmaceutical industries. The company uses a patent-pending combination of technologies to perform screening at the nanoliter scale, while preserving quality, speed and simplicity.
Combining genomics microarray printing technology and picoliter aerosol deposition, RBC has commercialized a novel technology that drives HTS to new levels of simplicity and efficiency.
More information: http://www.reactionbiology.com
Reaction Biology Corporation, 1764 Litchfield Turnpike, Suite 203 * Woodbridge, CT 06525 * 203-389-7407.
###
Copyright © 2006 by Reaction Biology Corporation and Send2Press® Newswire, a service of Neotrope® – all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.
• Story Title: Reaction Biology Corp. Awarded NIH R01 Screening Roadmap Grant for Microarray Screening Development
• REFERENCE KEYWORDS/TERMS: , , , , Devices and Research, , , .
IMPORTANT NOTICE: some content which is considered “old” or “archival” may reference an event which has already occurred; some content possibly considered “advertorial” may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Reaction Biology Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Mon, 13 Mar 2006 21:06:00 GMT].
USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.